Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Advancements in Anaphylaxis Management

Author(s): Alberto Alvarez-Perea*, Paula Cabrera-Freitag, Victoria Fuentes-Aparicio and Sonsoles Infante

Volume 29, Issue 3, 2023

Published on: 03 November, 2022

Page: [185 - 195] Pages: 11

DOI: 10.2174/1381612829666221021150946

Price: $65

Abstract

Anaphylaxis is defined as a severe life-threatening, generalized or systemic hypersensitivity reaction. Yet, anaphylaxis is often difficult to diagnose, leading to a delay in applying appropriate management. Epinephrine is the medication of choice for the immediate treatment of anaphylaxis. The rest of the actions to be taken during the acute anaphylaxis episode, including administering other medications, will depend on the response to epinephrine. Epinephrine auto-injectors (EAI) are the preferred method for administering the treatment of anaphylaxis in the community setting. However, there are multiple potential barriers to using epinephrine during an anaphylactic reaction related to the physicians and the patients themselves. Strategies to overcome gaps in the acute management of anaphylaxis include novel injection devices and research of new routes for epinephrine delivery. Electronic health solutions may also have a role at this level. Long-term management of anaphylaxis is focused on the prevention of new episodes. Etiologic diagnosis and patient education are key to this end. The application of health information technologies, such as telemedicine, social media, and mobile health, can be helpful for the long-term management of anaphylaxis. Additionally, some patients may benefit from long-term immunomodulatory and etiologic treatments when allergen avoidance implies negative consequences. This review article addresses the most recent advances regarding the integral management of anaphylaxis, including pharmacological and non-pharmacological measures.

« Previous Next »
[1]
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117(2): 391-7.
[http://dx.doi.org/10.1016/j.jaci.2005.12.1303] [PMID: 16461139]
[2]
Simons FER, Ardusso LRF, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014; 7(1): 9.
[http://dx.doi.org/10.1186/1939-4551-7-9] [PMID: 24920969]
[3]
Muraro A, Worm M, Alviani C, et al. EAACI guidelines: Anaphylaxis (2021 update). Allergy 2022; 77(2): 357-77.
[http://dx.doi.org/10.1111/all.15032] [PMID: 34343358]
[4]
Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145(4): 1082-123.
[http://dx.doi.org/10.1016/j.jaci.2020.01.017] [PMID: 32001253]
[5]
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13(10): 100472.
[http://dx.doi.org/10.1016/j.waojou.2020.100472] [PMID: 33204386]
[6]
Cardona V, Álvarez-Perea A, Ansotegui-Zubeldia IJ, et al. Clinical practice guide for anaphylaxis in Latin America (Galaxia-Latam). Rev Alerg Mex 2019; 66 (Suppl. 2): 1-39.
[http://dx.doi.org/10.29262/ram.v66i6.588] [PMID: 31443138]
[7]
Alvarez-Perea A, Tanno LK, Baeza ML. How to manage anaphylaxis in primary care. Clin Transl Allergy 2017; 7(1): 45.
[http://dx.doi.org/10.1186/s13601-017-0182-7] [PMID: 29238519]
[8]
Panesar SS, Javad S, de Silva D, et al. The epidemiology of anaphylaxis in Europe: A systematic review. Allergy 2013; 68(11): 1353-61.
[http://dx.doi.org/10.1111/all.12272] [PMID: 24117770]
[9]
Wood RA, Camargo CA Jr, Lieberman P, et al. Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol 2014; 133(2): 461-7.
[http://dx.doi.org/10.1016/j.jaci.2013.08.016] [PMID: 24144575]
[10]
Kastner M, Harada L, Waserman S. Gaps in anaphylaxis management at the level of physicians, patients, and the community: A systematic review of the literature. Allergy 2010; 65(4): 435-44.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02294.x] [PMID: 20028373]
[11]
Wang J, Sicherer SH, Nowak-Wegrzyn A. Primary care physicians’ approach to food-induced anaphylaxis: A survey. J Allergy Clin Immunol 2004; 114(3): 689-91.
[http://dx.doi.org/10.1016/j.jaci.2004.05.024] [PMID: 15446292]
[12]
Krugman SD, Chiaramonte DR, Matsui EC. Diagnosis and management of food-induced anaphylaxis: A national survey of pediatricians. Pediatrics 2006; 118(3): e554-60.
[http://dx.doi.org/10.1542/peds.2005-2906] [PMID: 16950947]
[13]
Lowe G, Kirkwood E, Harkness S. Survey of anaphylaxis management by general practitioners in Scotland. Scott Med J 2010; 55(3): 11-4.
[http://dx.doi.org/10.1258/rsmsmj.55.3.11] [PMID: 20795510]
[14]
Erkoçoğlu M, Civelek E, Azkur D, et al. Knowledge and attitudes of primary care physicians regarding food allergy and anaphylaxis in Turkey. Allergol Immunopathol 2013; 41(5): 292-7.
[http://dx.doi.org/10.1016/j.aller.2012.05.004] [PMID: 23031655]
[15]
Baççioğlu A, Yilmazel Uçar E. Level of knowledge about anaphylaxis among health care providers. Tuberk Toraks 2013; 61(2): 140-6.
[http://dx.doi.org/10.5578/tt.4812] [PMID: 23875592]
[16]
Gómez Galán C, Ferré Ybarz L, Peña Peloche MA, et al. Intention to prescribe self-injectable epinephrine: Are there differences depending on who assesses the patient post-reaction? Allergol Immunopathol 2015; 43(3): 286-91.
[http://dx.doi.org/10.1016/j.aller.2014.03.003] [PMID: 25097023]
[17]
Chung T, Gaudet L, Vandenberghe C, et al. Pre-hospital management of anaphylaxis in one Canadian Urban Centre. Resuscitation 2014; 85(8): 1077-82.
[http://dx.doi.org/10.1016/j.resuscitation.2014.04.004] [PMID: 24746784]
[18]
Kimchi N, Clarke A, Moisan J, et al. Anaphylaxis cases presenting to primary care paramedics in Quebec. Immun Inflamm Dis 2015; 3(4): 406-10.
[http://dx.doi.org/10.1002/iid3.78] [PMID: 26734462]
[19]
Saleh-Langenberg J, Dubois AEJ, Groenhof F, Kocks JWH, van der Molen T, Flokstra-de Blok BMJ. Epinephrine auto-injector prescriptions to food-allergic patients in primary care in The Netherlands. Allergy Asthma Clin Immunol 2015; 11(1): 28.
[http://dx.doi.org/10.1186/s13223-015-0094-9] [PMID: 26472961]
[20]
Simons FER, Sheikh A. Evidence-based management of anaphylaxis. Allergy 2007; 62(8): 827-9.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01433.x] [PMID: 17620059]
[21]
Simons FER. Pharmacologic treatment of anaphylaxis: Can the evidence base be strengthened? Curr Opin Allergy Clin Immunol 2010; 10(4): 384-93.
[http://dx.doi.org/10.1097/ACI.0b013e32833c2038] [PMID: 20585241]
[22]
Sheikh A, ten Broek V, Brown SGA, Simons FERH. 1 -antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62(8): 830-7.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01435.x] [PMID: 17620060]
[23]
Simons KJ, Simons FER. Epinephrine and its use in anaphylaxis: Current issues. Curr Opin Allergy Clin Immunol 2010; 10(4): 354-61.
[http://dx.doi.org/10.1097/ACI.0b013e32833bc670] [PMID: 20543673]
[24]
Kemp SF, Lockey RF, Simons FER. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy 2008; 63(8): 1061-70.
[http://dx.doi.org/10.1111/j.1398-9995.2008.01733.x] [PMID: 18691308]
[25]
McLean-Tooke APC, Bethune CA, Fay AC, Spickett GP. Adrenaline in the treatment of anaphylaxis: What is the evidence? BMJ 2003; 327(7427): 1332-5.
[http://dx.doi.org/10.1136/bmj.327.7427.1332]
[26]
Brown SGA. Cardiovascular aspects of anaphylaxis: Implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol 2005; 5(4): 359-64.
[http://dx.doi.org/10.1097/01.all.0000174158.78626.35] [PMID: 15985820]
[27]
Anchor J, Settipane RA. Appropriate use of epinephrine in anaphylaxis. Am J Emerg Med 2004; 22(6): 488-90.
[http://dx.doi.org/10.1016/j.ajem.2004.07.016] [PMID: 15520945]
[28]
Fleming JT, Clark S, Camargo CA Jr, Rudders SA. Early treatment of food-induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization. J Allergy Clin Immunol Pract 2015; 3(1): 57-62.
[http://dx.doi.org/10.1016/j.jaip.2014.07.004] [PMID: 25577619]
[29]
Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in Ontario: A retrospective review of cases from 1986 to 2011. Allergy Asthma Clin Immunol 2014; 10(1): 38.
[http://dx.doi.org/10.1186/1710-1492-10-38] [PMID: 25670935]
[30]
Oya S, Kinoshita K, Daya M, Kinoshita H. Characteristics of anaphylactic reactions: A prospective observational study in Japan. J Emerg Med 2020; 59(6): 812-9.
[http://dx.doi.org/10.1016/j.jemermed.2020.07.004] [PMID: 32917450]
[31]
Simons FER, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101(1): 33-7.
[http://dx.doi.org/10.1016/S0091-6749(98)70190-3] [PMID: 9449498]
[32]
Simons FER, Gu X, Simons KJ. Epinephrine absorption in adults: Intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108(5): 871-3.
[http://dx.doi.org/10.1067/mai.2001.119409] [PMID: 11692118]
[33]
Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis: Higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract 2015; 3(1): 76-80.
[http://dx.doi.org/10.1016/j.jaip.2014.06.007] [PMID: 25577622]
[34]
Manivannan V, Campbell RL, Bellolio MF, Stead LG, Li JTC, Decker WW. Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009; 103(5): 395-400.
[http://dx.doi.org/10.1016/S1081-1206(10)60358-4] [PMID: 19927537]
[35]
Alvarez-Perea A, Tomás-Pérez M, Ameiro B, Zubeldia JM, Baeza ML. When is epinephrine prescribed for anaphylaxis? Ann Allergy Asthma Immunol 2019; 122(3): 339-40.
[http://dx.doi.org/10.1016/j.anai.2018.11.028] [PMID: 30529549]
[36]
Soller L, Fragapane J, Ben-Shoshan M, et al. Possession of epinephrine auto-injectors by Canadians with food allergies. J Allergy Clin Immunol 2011; 128(2): 426-8.
[http://dx.doi.org/10.1016/j.jaci.2011.05.015] [PMID: 21684589]
[37]
Munoz de Baena Albarracin M, Skrabski F, Pérez-Pallisé E. -Barrera IV, Baeza ML, Alvarez-Perea AL. Use of epinephrine in paedriatric anaphylaxis: Beyond the emergency department. J Allergy Clin Immunol 2022; 149(2): AB134.
[http://dx.doi.org/10.1016/j.jaci.2021.12.455]
[38]
Alvarez Perea A, Fuentes Aparicio V, Cabrera Freitag P, et al. Is self-injectable epinephrine being used by children with food allergy? J Investig Allergol Clin Immunol 2019; 29(6): 461-3.
[http://dx.doi.org/10.18176/jiaci.0426] [PMID: 31825314]
[39]
Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: Missed opportunities. J Asthma Allergy 2018; 11: 143-51.
[http://dx.doi.org/10.2147/JAA.S159400] [PMID: 29950873]
[40]
Hayman GR, Bansal JA, Bansal AS. Knowledge about using auto-injectable adrenaline: Review of patients’ case notes and interviews with general practitioners. BMJ 2003; 327(7427): 1328.
[http://dx.doi.org/10.1136/bmj.327.7427.1328] [PMID: 14656843]
[41]
Westermann-Clark E, Pepper AN, Lockey RF. Economic considerations in the treatment of systemic allergic reactions. J Asthma Allergy 2018; 11: 153-8.
[http://dx.doi.org/10.2147/JAA.S159851] [PMID: 29950874]
[42]
Brooks C, Coffman A, Erwin E, Mikhail I. Diagnosis and treatment of food allergic reactions in pediatric emergency settings. Ann Allergy Asthma Immunol 2017; 119(5): 467-8.
[http://dx.doi.org/10.1016/j.anai.2017.08.287] [PMID: 29150075]
[43]
Boswell B, Rudders SA, Brown JC. Emerging therapies in anaphylaxis: Alternatives to intramuscular administration of epinephrine. Curr Allergy Asthma Rep 2021; 21(3): 18.
[http://dx.doi.org/10.1007/s11882-021-00994-0] [PMID: 33666759]
[44]
Edwards ES, Gunn R, Simons ER, et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol 2013; 111(2): 132-7.
[http://dx.doi.org/10.1016/j.anai.2013.06.002] [PMID: 23886232]
[45]
Camargo CA, Guana A, Wang S, Simons FER. Auvi-Q versus EpiPen: Preferences of adults, caregivers, and children. J Allergy Clin Immunol Pract 2013; 1: 266-72.
[46]
ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA 2019. Available from: https://ir.alk.net/news-releases/news-release-details/alk-announces-new-epinephrine-auto-injector-strategy-based
[47]
Bardou M, Luu M, Walker P, Auriel C, Castano X. Efficacy of a novel prefilled, single-use, needle-free device (Zeneo®) in achieving intramuscular agent delivery: An observational study. Adv Ther 2017; 34(1): 252-60.
[http://dx.doi.org/10.1007/s12325-016-0452-0] [PMID: 27928757]
[48]
Sala-Cunill A, Luengo O, Curran A, et al. Digital technology for anaphylaxis management impact on patient behaviour: A randomized clinical trial. Allergy 2021; 76(5): 1507-16.
[http://dx.doi.org/10.1111/all.14626] [PMID: 33043475]
[49]
Alvarez-Perea A, Sánchez-García S, Muñoz Cano R, Antolín-Amérigo D, Tsilochristou O, Stukus DR. Impact Of “eHealth” in allergic diseases and allergic patients. J Investig Allergol Clin Immunol 2019; 29(2): 94-102.
[http://dx.doi.org/10.18176/jiaci.0354] [PMID: 30457105]
[50]
WYSS Insitute Project Abbie. 2015. Available from: https://wyss.harvard.edu/technology/project-abbie/
[51]
Dretchen KL, Mesa Z, Robben M, et al. Intranasal epinephrine in dogs: Pharmacokinetic and heart rate effects. Pharmacol Res Perspect 2020; 8(2): e00587.
[http://dx.doi.org/10.1002/prp2.587] [PMID: 32302068]
[52]
Srisawat C, Nakponetong K, Benjasupattananun P, et al. A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. Asian Pac J Allergy Immunol 2016; 34(1): 38-43.
[PMID: 26994624]
[53]
Lockey R, Simons FE, Kaliner M, Lieberman P, Tanimoto S, Lowenthal R. Comparison of the pharmacokinetics and pharmacodynamics of epinephrine after Intranasal (IN), Intramuscular (IM) and Subcutaneous (SC) administration in three landmark studies. J Allergy Clin Immunol 2020; 145(2): AB78.
[http://dx.doi.org/10.1016/j.jaci.2019.12.669]
[54]
Tanimoto S, Simons FE, Lockey R, Lieberman P, Kaliner M, Lowenthal R. A phase 1, five-period, five-treatment, randomized crossover study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of epinephrine after administration of Intranasal (IN) ARS-1 and Intramuscular (IM) epinephrine to healthy volunteers. J Allergy Clin Immunol 2020; 145(2): AB77.
[http://dx.doi.org/10.1016/j.jaci.2019.12.668]
[55]
Gu X, Simons KJ, Simons FER. Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. Biopharm Drug Dispos 2002; 23(5): 213-6.
[http://dx.doi.org/10.1002/bdd.312] [PMID: 12116053]
[56]
Rawas-Qalaji MM, Simons FER, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis. J Allergy Clin Immunol 2006; 117(2): 398-403.
[http://dx.doi.org/10.1016/j.jaci.2005.12.1310] [PMID: 16461140]
[57]
Rawas-Qalaji MM, Werdy S, Rachid O, Simons FER, Simons KJ. Sublingual diffusion of epinephrine microcrystals from rapidly disintegrating tablets for the potential first-aid treatment of anaphylaxis: In vitro and ex vivo study. AAPS PharmSciTech 2015; 16(5): 1203-12.
[http://dx.doi.org/10.1208/s12249-015-0306-0] [PMID: 25732373]
[58]
Rachid O, Rawas-Qalaji M, Simons K. Epinephrine in anaphylaxis: Preclinical study of pharmacokinetics after sublingual administration of taste-masked tablets for potential pediatric use. Pharmaceutics 2018; 10(1): 24.
[http://dx.doi.org/10.3390/pharmaceutics10010024] [PMID: 29439456]
[59]
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis. Available from: https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-fda-fast-track-designation-for-aqst-108-sublingual
[60]
Simons FER, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics 2000; 106(5): 1040-4.
[http://dx.doi.org/10.1542/peds.106.5.1040] [PMID: 11061773]
[61]
Breuer C, Wachall B, Gerbeth K, Abdel-Tawab M, Fuhr U. Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. Eur J Clin Pharmacol 2013; 69(6): 1303-10.
[http://dx.doi.org/10.1007/s00228-012-1465-5] [PMID: 23292159]
[62]
Frechen S, Suleiman AA, Mohammad Nejad Sigaroudi A, Wachall B, Fuhr U. Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler. Drug Metab Pharmacokinet 2015; 30(6): 391-9.
[http://dx.doi.org/10.1016/j.dmpk.2015.08.002] [PMID: 26615448]
[63]
Tanno LK, Alvarez-Perea A, Pouessel G. Therapeutic approach of anaphylaxis. Curr Opin Allergy Clin Immunol 2019; 19(4): 393-401.
[http://dx.doi.org/10.1097/ACI.0000000000000539] [PMID: 31058676]
[64]
Welzel T, Ziesenitz VC, Seitz S, Donner B, van den Anker JN. Management of anaphylaxis and allergies in patients with long QT syndrome. Ann Allergy Asthma Immunol 2018; 121(5): 545-51.
[http://dx.doi.org/10.1016/j.anai.2018.07.027] [PMID: 30059791]
[65]
Francuzik W, Dölle S, Worm M. Risk factors and treatment of refractory anaphylaxis - A review of case reports. Expert Rev Clin Immunol 2018; 14(4): 307-14.
[http://dx.doi.org/10.1080/1744666X.2018.1450140] [PMID: 29513116]
[66]
Thomas M, Crawford I. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22(4): 272-3.
[http://dx.doi.org/10.1136/emj.2005.023507] [PMID: 15788828]
[67]
Rukma P. Glucagon for refractory anaphylaxis. Am J Ther 2019; 26(6): e755-6.
[http://dx.doi.org/10.1097/MJT.0000000000000910] [PMID: 30648988]
[68]
White JL, Greger KC, Lee S, Kahoud RJ, Li JT, Lohse CM. Patients taking beta-blockers do not require increased doses of epinephrine for anaphylaxis. J Allergy Clin Immunol Pract 2017; 6(5): 1553-58, e1.
[PMID: 29449164]
[69]
Kemp AM, Kemp SF. Pharmacotherapy in refractory anaphylaxis. Curr Opin Allergy Clin Immunol 2014; 14(4): 371-8.
[http://dx.doi.org/10.1097/ACI.0000000000000080] [PMID: 24945376]
[70]
Dhami S, Panesar SS, Roberts G, et al. Management of anaphylaxis: A systematic review. Allergy 2014; 69(2): 168-75.
[http://dx.doi.org/10.1111/all.12318] [PMID: 24251536]
[71]
Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117(2): 367-77.
[http://dx.doi.org/10.1016/j.jaci.2005.12.002] [PMID: 16461138]
[72]
Alvarez-Perea A, Tomás-Pérez M, Martínez-Lezcano P, et al. Anaphylaxis in adolescent/adult patients treated in the emergency department: Differences between initial impressions and the definitive diagnosis. J Investig Allergol Clin Immunol 2015; 25(4): 288-94.
[PMID: 26310044]
[73]
Alvarez-Perea A, Ameiro B, Morales C, et al. Anaphylaxis in the pediatric emergency department: Analysis of 133 cases after an allergy workup. J Allergy Clin Immunol Pract 2017; 5(5): 1256-63.
[http://dx.doi.org/10.1016/j.jaip.2017.02.011] [PMID: 28389303]
[74]
Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: Report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126(6) (Suppl.): 1105-18.
[http://dx.doi.org/10.1016/j.jaci.2010.10.008] [PMID: 21134576]
[75]
Ellis BC, Brown SGA. Parenteral antihistamines cause hypotension in anaphylaxis. Emerg Med Australas 2013; 25(1): 92-3.
[http://dx.doi.org/10.1111/1742-6723.12028] [PMID: 23379461]
[76]
Park JH, Godbold JH, Chung D, Sampson HA, Wang J. Comparison of cetirizine and diphenhydramine in the treatment of acute food-induced allergic reactions. J Allergy Clin Immunol 2011; 128(5): 1127-8.
[http://dx.doi.org/10.1016/j.jaci.2011.08.026] [PMID: 21945608]
[77]
Grunau BE, Wiens MO, Rowe BH, et al. Emergency department corticosteroid use for allergy or anaphylaxis is not associated with decreased relapses. Ann Emerg Med 2015; 66(4): 381-9.
[http://dx.doi.org/10.1016/j.annemergmed.2015.03.003] [PMID: 25820033]
[78]
Alqurashi W, Ellis AK. Do corticosteroids prevent biphasic anaphylaxis? J Allergy Clin Immunol Pract 2017; 5(5): 1194-205.
[http://dx.doi.org/10.1016/j.jaip.2017.05.022] [PMID: 28888249]
[79]
Okubo Y, Michihata N, Morisaki N, et al. Effects of glucocorticoids on hospitalized children with anaphylaxis. Pediatr Emerg Care 2021; 37(5): 255-9.
[http://dx.doi.org/10.1097/PEC.0000000000001544] [PMID: 29912092]
[80]
Choo KJL, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010; 65(10): 1205-11.
[http://dx.doi.org/10.1111/j.1398-9995.2010.02424.x] [PMID: 20584003]
[81]
Liyanage CK, Galappatthy P, Seneviratne SL. Corticosteroids in management of anaphylaxis; A systematic review of evidence. Eur Ann Allergy Clin Immunol 2017; 49(5): 196-207.
[http://dx.doi.org/10.23822/EurAnnACI.1764-1489.15] [PMID: 28884986]
[82]
Sheikh A. Glucocorticosteroids for the treatment and prevention of anaphylaxis. Curr Opin Allergy Clin Immunol 2013; 13(3): 263-7.
[http://dx.doi.org/10.1097/ACI.0b013e32836097f4] [PMID: 23507835]
[83]
Lin R, Curry A, Pesola G, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36(5): 462-8.
[http://dx.doi.org/10.1016/S0196-0644(00)43749-2] [PMID: 11054200]
[84]
Nurmatov UB, Rhatigan E, Simons FER, Sheikh A. H2-antihistamines for the treatment of anaphylaxis with and without shock: A systematic review. Ann Allergy Asthma Immunol 2014; 112(2): 126-31.
[http://dx.doi.org/10.1016/j.anai.2013.11.010] [PMID: 24468252]
[85]
Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012; (3): CD008596.
[PMID: 22419335]
[86]
McCartney SL, Duce L, Ghadimi K. Intraoperative vasoplegia. Curr Opin Anaesthesiol 2018; 31(1): 43-9.
[http://dx.doi.org/10.1097/ACO.0000000000000548] [PMID: 29176374]
[87]
Dewachter P, Mouton-Faivre C, Emala CW, Riou B. Anaphylaxis and anesthesia. Anesthesiology 2009; 111(5): 1141-50.
[http://dx.doi.org/10.1097/ALN.0b013e3181bbd443] [PMID: 19858877]
[88]
Barthel F, Stojeba N, Lyons G, Biermann C, Diemunsch P. Sugammadex in rocuronium anaphylaxis: Dose matters. Br J Anaesth 2012; 109(4): 646-7.
[http://dx.doi.org/10.1093/bja/aes332] [PMID: 22976863]
[89]
La Cruz ID, Errando C, Calaforra S. Treatment of anaphylaxis to rocuronium with sugammadex: A case report with bronchospasm as the only symptom. Turkish J Anesth Reanim 2019; 47(1): 69-72.
[90]
Binczak M, Fischler M, Le Guen M. Efficacy of sugammadex in preventing skin test reaction in a patient with confirmed rocuronium anaphylaxis: A case report. A A Pract 2019; 13(1): 17-9.
[http://dx.doi.org/10.1213/XAA.0000000000000973] [PMID: 30720535]
[91]
Platt PR, Clarke RC, Johnson GH, Sadleir PHM. Efficacy of sugammadex in rocuronium-induced or antibiotic-induced anaphylaxis. A case-control study. Anaesthesia 2015; 70(11): 1264-7.
[http://dx.doi.org/10.1111/anae.13178] [PMID: 26259130]
[92]
Campbell RL, Park MA, Kueber MA Jr, Lee S, Hagan JB. Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis. J Allergy Clin Immunol Pract 2015; 3(1): 88-93.
[http://dx.doi.org/10.1016/j.jaip.2014.07.011] [PMID: 25577624]
[93]
Altman AM, Camargo CAJ, Simons FER, Lieberman PPL, Sampson HA, Schwartz LB. Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. J Allergy Clin Immunol 2014; 127: 461-7.
[94]
Alvarez-Perea A, Dimov V, Popescu FD, Zubeldia JM. The applications of eHealth technologies in the management of asthma and allergic diseases. Clin Transl Allergy 2021; 11(7): e12061.
[http://dx.doi.org/10.1002/clt2.12061] [PMID: 34504682]
[95]
Staicu ML, Holly AM, Conn KM, Ramsey A. The use of telemedicine for penicillin allergy skin testing. J Allergy Clin Immunol Pract 2018; 6(6): 2033-40.
[http://dx.doi.org/10.1016/j.jaip.2018.04.038] [PMID: 29751152]
[96]
Thomas I, Siew LQC, Rutkowski K. Synchronous telemedicine in allergy: Lessons learned and transformation of care during the COVID-19 pandemic. J Allergy Clin Immunol Pract 2021; 9(1): 170-176.e1.
[http://dx.doi.org/10.1016/j.jaip.2020.10.013] [PMID: 33091636]
[97]
González-Pérez R, Sánchez-Machín I, Poza-Guedes P, Matheu V, Álava-Cruz C, Mederos Luís E. Pertinence of telehealth in a rush conversion to virtual allergy practice during the COVID-19 outbreak. J Investig Allergol Clin Immunol 2021; 31(1): 78-80.
[http://dx.doi.org/10.18176/jiaci.0597] [PMID: 32508306]
[98]
Amorim P, Brito D, Castelo-Branco M, Fàbrega C, Gomes Da Costa F, Martins H. Telehealth opportunities in the COVID-19 pandemic early days: What happened, did not happen, should have happened, and must happen in the near future? Telemed e-Health 2021; 27: 1194-99.
[99]
Bermejo-Becerro A, Skrabski F, Pérez-Pallisé E, Rodríguez-Hermida S, Zubeldia JM, Alvarez-Perea A. Patient’s perceived quality and satisfaction of teleconsultation services in an allergy department during COVID-19 pandemic era. J Allergy Clin Immunol 2021; 147(2): AB112.
[http://dx.doi.org/10.1016/j.jaci.2020.12.413]
[100]
Jokinen A, Stolt M, Suhonen R. Ethical issues related to eHealth: An integrative review. Nurs Ethics 2021; 28(2): 253-71.
[PMID: 32930041]
[101]
Brockow K, Schallmayer S, Beyer K, et al. Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis. Allergy 2015; 70(2): 227-35.
[http://dx.doi.org/10.1111/all.12548] [PMID: 25407693]
[102]
Salter SM, Vale S, Sanfilippo FM, Loh R, Clifford RM. Long-term effectiveness of online anaphylaxis education for pharmacists. Am J Pharm Educ 2014; 78(7): 136.
[http://dx.doi.org/10.5688/ajpe787136] [PMID: 25258441]
[103]
Simons FER, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World allergy organization anaphylaxis guidelines. World Allergy Organ J 2015; 8(1): 32.
[http://dx.doi.org/10.1186/s40413-015-0080-1] [PMID: 26525001]
[104]
European Commission; Directorate-General for the Information Society and Media, E-Communications and the digital single market: Report, European Commission. Available from:. 2016.
[http://dx.doi.org/10.2759/388948]
[105]
ONTSI. Citizens before e-Health. Opinions and expectations of citizens about the use and application of ICT in the health field Madrid: Government of Spain. 2016. Available from: http:/www.ontsi.red.es/ontsi/sites/ontsi/files/los_ciudadanos_ante_la_e-sanidad.pdf
[106]
Carpio-Escalona LV, González-de-Olano D. Use of the Internet by patients attending allergy clinics and its potential as a tool that better meets patients’ needs. J Allergy Clin Immunol Pract 2018; 6(3): 1064-6.
[http://dx.doi.org/10.1016/j.jaip.2017.10.034] [PMID: 29196086]
[107]
Alvarez-Perea A, Cabrera-Freitag P, Fuentes-Aparicio V, Infante S, Zapatero L, Zubeldia JM. Social media as a tool for the management of food allergy in children. J Investig Allergol Clin Immunol 2018; 28(4): 233-40.
[http://dx.doi.org/10.18176/jiaci.0235] [PMID: 29411703]
[108]
Alvarez-Perea A, Ojeda P, Zubeldia JM. Trends in twitter use during the annual meeting of the spanish society of allergology and clinical immunology (2013-2016). J Allergy Clin Immunol Pract 2018; 6(1): 310-2.
[http://dx.doi.org/10.1016/j.jaip.2017.07.031] [PMID: 28939139]
[109]
Gabarron E, Fernandez-Luque L, Armayones M, Lau AYS. Identifying measures used for assessing quality of youtube videos with patient health information: A review of current literature. Interact J Med Res 2013; 2(1): e6.
[http://dx.doi.org/10.2196/ijmr.2465] [PMID: 23612432]
[110]
Dimov V, Eidelman F. Utilizing social networks, blogging and YouTube in allergy and immunology practices. Expert Rev Clin Immunol 2015; 11(10): 1065-8.
[http://dx.doi.org/10.1586/1744666X.2015.1065731] [PMID: 26163316]
[111]
Reddy K, Kearns M, Arango AS, et al. YouTube and food allergy: An appraisal of the educational quality of information. Pediatr Allergy Immunol 2018; 29(4): 410-6.
[http://dx.doi.org/10.1111/pai.12885] [PMID: 29512839]
[112]
Rosenzweig D, Nickels AS. Asthma Inhaler: Evaluation of visual social media depictions of inhalers and spacers. J Allergy Clin Immunol Pract 2017; 5(6): 1787-8.
[http://dx.doi.org/10.1016/j.jaip.2017.04.029] [PMID: 28533122]
[113]
Solnick RE, Chao G, Ross RD, Kraft-Todd GT, Kocher KE. Emergency physicians and personal narratives improve the perceived effectiveness of COVID‐19 public health recommendations on social media: A randomized experiment. Acad Emerg Med 2021; 28(2): 172-83.
[http://dx.doi.org/10.1111/acem.14188] [PMID: 33263357]
[114]
Barnes A, DelBruno J. Food allergen detection methods and systems using molecularly imprinted polymers US20160209420A1, 2016.
[115]
Allergy Amulet. Available from: http://www.allergyamulet.com
[116]
Huckvale K, Morrison C, Ouyang J, Ghaghda A, Car J. The evolution of mobile apps for asthma: An updated systematic assessment of content and tools. BMC Med 2015; 13(1): 58.
[http://dx.doi.org/10.1186/s12916-015-0303-x] [PMID: 25857569]
[117]
Castells MC. A new era for drug desensitizations. J Allergy Clin Immunol Pract 2015; 3(4): 639-40.
[http://dx.doi.org/10.1016/j.jaip.2015.05.006] [PMID: 26164579]
[118]
Alfaya Arias T, Soriano Gómis V, Soto Mera T, et al. Key issues in hymenoptera venom allergy: An update. J Investig Allergol Clin Immunol 2017; 27(1): 19-31.
[http://dx.doi.org/10.18176/jiaci.0123] [PMID: 28211342]
[119]
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy 2017; 72(8): 1133-47.
[http://dx.doi.org/10.1111/all.13124] [PMID: 28058751]
[120]
El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol 2016; 50(1): 84-96.
[http://dx.doi.org/10.1007/s12016-015-8490-y] [PMID: 26048266]
[121]
de las Vecillas Sánchez L, Alenazy L, Garcia-Neuer M, Castells M. Drug hypersensitivity and desensitizations: Mechanisms and new approaches. Int J Mol Sci 2017; 18(6): 1316.
[http://dx.doi.org/10.3390/ijms18061316] [PMID: 28632196]
[122]
Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018; 73(4): 744-64.
[http://dx.doi.org/10.1111/all.13262] [PMID: 28748641]
[123]
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018; 73(4): 799-815.
[http://dx.doi.org/10.1111/all.13319] [PMID: 29205393]
[124]
Rodríguez del Río P, Alvarez-Perea A, Blumchen K, Caimmi D, Caubet JC, Konstantinopoulos AP. Food immunotherapy practice: Nation differences across Europe, The FIND project. Allergy Eur J Allergy Clin Immunol 2021; 1-13.
[125]
Tanno LK, Demoly P. Biologicals for the prevention of anaphylaxis. Curr Opin Allergy Clin Immunol 2021; 21(3): 303-8.
[http://dx.doi.org/10.1097/ACI.0000000000000737] [PMID: 33625038]
[126]
Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: A systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol 2020; 16(1): 49.
[http://dx.doi.org/10.1186/s13223-020-00442-0] [PMID: 32565844]
[127]
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368(10): 924-35.
[http://dx.doi.org/10.1056/NEJMoa1215372] [PMID: 23432142]
[128]
Fala L. Nucala (Mepolizumab): First IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Heal drug benefits 2016; 9: 106-10.
[129]
Máspero J. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: Clinical trial evidence and future prospects. Ther Adv Respir Dis 2017; 11(8): 311-25.
[http://dx.doi.org/10.1177/1753465817717134] [PMID: 28683596]
[130]
Markham A. Benralizumab: First global approval. Drugs 2018; 78(4): 505-11.
[http://dx.doi.org/10.1007/s40265-018-0876-8] [PMID: 29464664]
[131]
Mullard A. FDA approves dupilumab for severe eczema. Nat Rev Drug Discov 2017; 16(5): 305.
[PMID: 28450716]
[132]
Lieberman JA, Chehade M. Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep 2013; 13(1): 78-84.
[http://dx.doi.org/10.1007/s11882-012-0316-x] [PMID: 23065311]
[133]
Pfützner W, Schuppe M. Use of biologics in allergen immunotherapy. Allergol Select 2021; 5(1): 108-18.
[http://dx.doi.org/10.5414/ALX02206E] [PMID: 33634221]
[134]
Cardet JC, Casale TB. New insights into the utility of omalizumab. J Allergy Clin Immunol 2019; 143(3): 923-926.e1.
[http://dx.doi.org/10.1016/j.jaci.2019.01.016] [PMID: 30690050]
[135]
MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139(3): 873-881.e8.
[http://dx.doi.org/10.1016/j.jaci.2016.08.010] [PMID: 27609658]
[136]
Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol 2016; 137(4): 1103-1110.e11.
[http://dx.doi.org/10.1016/j.jaci.2015.10.005] [PMID: 26581915]
[137]
Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014; 10(1): 7.
[http://dx.doi.org/10.1186/1710-1492-10-7] [PMID: 24576338]
[138]
Worm M, Francuzik W, Dölle-Bierke S, Alexiou A. Use of biologics in food allergy management. Allergol Select 2021; 5(1): 103-7.
[http://dx.doi.org/10.5414/ALX02141E] [PMID: 33634220]
[139]
Fernandez J, Ruano-Zaragoza M, Blanca-Lopez N. Omalizumab and other biologics in drug desensitization. Curr Opin Allergy Clin Immunol 2020; 20(4): 333-7.
[http://dx.doi.org/10.1097/ACI.0000000000000648] [PMID: 32398420]
[140]
Carter MC, Maric I, Brittain EH, et al. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. J Allergy Clin Immunol 2021; 147(3): 1004-1010.e2.
[http://dx.doi.org/10.1016/j.jaci.2020.11.005] [PMID: 33220353]
[141]
Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: A review of the literature and case report. J Allergy Clin Immunol Pract 2014; 2(3): 266-70.
[http://dx.doi.org/10.1016/j.jaip.2014.03.009] [PMID: 24811015]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy